CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 100 enrolled
Drug / intervention
Ondansetron +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05692245
NCT05692245Phase 4Completed
CompareCT.gov

Dexamethasone vs Ondansetron as the First-line Antiemetic to Prevent Postoperative Nausea and Vomiting After Cesarean Delivery

Beth Israel Deaconess Medical Center·interventional·Posted Jan 20, 2023·Updated Mar 13, 2026

In Brief

A Phase 4 clinical trial evaluating Ondansetron and Dexamethasone for Nausea and Vomiting, Postoperative and Cesarean Section Complications. Completed, enrolled 100 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to compare medications in women having a cesarean delivery. The main question it aims to answer are: • Which medication is better to use as a first-line prevention agent for nausea and vomiting Participants will rate their nausea, pain and other symptoms after surgery Researchers will compare two drugs, ondansetron and dexamethasone to see if the side effects of pain medications are improved after cesarean.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNausea and Vomiting, Postoperative, Cesarean Section Complications
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedJan 20, 2023
Enrollment StartMar 30, 2023
Primary CompletionApr 30, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.4 years ago

Interventions

Ondansetrondrug

Administered Medication

Dexamethasonedrug

Administered Medication